GFR-话题@MedSci

#GFR#

483篇内容 | 2614人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534360, encodeId=5919153436003, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：ASP8273治疗EGFR突变非小细胞肺癌, objectType=article, longId=123731, objectId=8ca8123e31c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ca8123e31c7, replyNumber=0, likeNumber=0, createdTime=2017-12-19, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ca8123e31c7, moduleTitle=CLIN CANCER RES：ASP8273治疗EGFR突变非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ca8123e31c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534359, encodeId=1490153435987, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Sci Rep：计算机辅助结节评估和风险收益（CANARY）可以促进对肺腺癌EGFR突变状态的非侵入性预测, objectType=article, longId=123689, objectId=fd0812368904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd0812368904, replyNumber=0, likeNumber=0, createdTime=2017-12-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd0812368904, moduleTitle=Sci Rep：计算机辅助结节评估和风险收益（CANARY）可以促进对肺腺癌EGFR突变状态的非侵入性预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd0812368904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534358, encodeId=5a481534358da, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CFDA批准上市Giotrif®（阿法替尼），单药治疗EGFR敏感突变的晚期非小细胞肺癌, objectType=article, longId=121901, objectId=1fe812190145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fe812190145, replyNumber=0, likeNumber=51, createdTime=2017-12-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fe812190145, moduleTitle=CFDA批准上市Giotrif®（阿法替尼），单药治疗EGFR敏感突变的晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fe812190145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534357, encodeId=0d5d153435ee3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：BGJ398治疗FGFR改变晚期胆管癌, objectType=article, longId=121790, objectId=0dc5121e9000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0dc5121e9000, replyNumber=0, likeNumber=58, createdTime=2017-12-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0dc5121e9000, moduleTitle=JCO：BGJ398治疗FGFR改变晚期胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0dc5121e9000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534356, encodeId=b0f415343567d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药, objectType=article, longId=121469, objectId=2c331214690e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c331214690e, replyNumber=0, likeNumber=74, createdTime=2017-11-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c331214690e, moduleTitle=CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c331214690e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534355, encodeId=021c15343555d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet oncol：吉非替尼相比长春瑞滨联合顺铂治疗，可显著延长携带EGFR突变的晚期非小细胞肺癌术后患者的无病存活期。, objectType=article, longId=121145, objectId=f91412114508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f91412114508, replyNumber=0, likeNumber=68, createdTime=2017-11-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f91412114508, moduleTitle=Lancet oncol：吉非替尼相比长春瑞滨联合顺铂治疗，可显著延长携带EGFR突变的晚期非小细胞肺癌术后患者的无病存活期。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f91412114508)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534354, encodeId=91031534354a5, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：EGFR扩增胶质瘤中EGFRvⅢ阳性的预后意义, objectType=article, longId=120825, objectId=c78e120825c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c78e120825c1, replyNumber=0, likeNumber=78, createdTime=2017-11-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c78e120825c1, moduleTitle=CLIN CANCER RES：EGFR扩增胶质瘤中EGFRvⅢ阳性的预后意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c78e120825c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534353, encodeId=5794153435355, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=阿法替尼（吉泰瑞®）--第二代EGFR-TKI肺癌靶向药物在中国获批, objectType=article, longId=120579, objectId=4e541205e950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e541205e950, replyNumber=0, likeNumber=0, createdTime=2017-11-19, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e541205e950, moduleTitle=阿法替尼（吉泰瑞®）--第二代EGFR-TKI肺癌靶向药物在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e541205e950)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534352, encodeId=23aa1534352be, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=陈建华教授：晚期NSCLC一线EGFR-TKI耐药进展后的治疗策略, objectType=article, longId=119408, objectId=f1bc1194081a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bc1194081a, replyNumber=0, likeNumber=55, createdTime=2017-11-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bc1194081a, moduleTitle=陈建华教授：晚期NSCLC一线EGFR-TKI耐药进展后的治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bc1194081a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534351, encodeId=a4b8153435182, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=刘晓晴教授对话张树才教授：三代EGFR-TKI的对比与排兵布阵, objectType=article, longId=119396, objectId=8df0119396d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8df0119396d1, replyNumber=0, likeNumber=86, createdTime=2017-11-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8df0119396d1, moduleTitle=刘晓晴教授对话张树才教授：三代EGFR-TKI的对比与排兵布阵, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8df0119396d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534350, encodeId=f36a15343508a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Exp Clin Cancer Res：circGFRA1或是三阴乳腺癌潜在的治疗靶点, objectType=article, longId=118802, objectId=a3df118802f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3df118802f9, replyNumber=0, likeNumber=129, createdTime=2017-11-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3df118802f9, moduleTitle=J Exp Clin Cancer Res：circGFRA1或是三阴乳腺癌潜在的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3df118802f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534349, encodeId=b1ae1534349b4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点, objectType=article, longId=118378, objectId=d0071183e824, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0071183e824, replyNumber=0, likeNumber=65, createdTime=2017-11-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0071183e824, moduleTitle=[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0071183e824)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534348, encodeId=d4a315343481b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol：血液肿瘤DNA测序指导EGFR阳性肺癌两种靶向药物序贯使用, objectType=article, longId=117341, objectId=d5fc11e34189, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5fc11e34189, replyNumber=0, likeNumber=57, createdTime=2017-10-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5fc11e34189, moduleTitle=J Thorac Oncol：血液肿瘤DNA测序指导EGFR阳性肺癌两种靶向药物序贯使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5fc11e34189)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534347, encodeId=23e8153434ee9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Brit J Cancer：RAS野生型转移性结肠癌患者接受抗EGFR治疗响应的蛋白预测生物标志物, objectType=article, longId=117254, objectId=b6b411e25414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6b411e25414, replyNumber=0, likeNumber=73, createdTime=2017-10-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6b411e25414, moduleTitle=Brit J Cancer：RAS野生型转移性结肠癌患者接受抗EGFR治疗响应的蛋白预测生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6b411e25414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534346, encodeId=2ddb1534346df, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=【WCLC 2017】韩宝惠教授解读安罗替尼更新数据：EGFR野生和突变型安罗替尼均获得双阳性结果, objectType=article, longId=116884, objectId=b99c116884cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b99c116884cd, replyNumber=0, likeNumber=81, createdTime=2017-10-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b99c116884cd, moduleTitle=【WCLC 2017】韩宝惠教授解读安罗替尼更新数据：EGFR野生和突变型安罗替尼均获得双阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b99c116884cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534345, encodeId=26ee153434523, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=[WCLC精彩研究]支气管镜冲洗液用于EGFR突变检测, objectType=article, longId=116799, objectId=0fa8116e99cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fa8116e99cf, replyNumber=0, likeNumber=61, createdTime=2017-10-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fa8116e99cf, moduleTitle=[WCLC精彩研究]支气管镜冲洗液用于EGFR突变检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fa8116e99cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534344, encodeId=26161534344c4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=【WCLC 2017】FLAURA研究伴随诊断结果公布：血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致, objectType=article, longId=116656, objectId=7181116656ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7181116656ed, replyNumber=0, likeNumber=60, createdTime=2017-10-20, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7181116656ed, moduleTitle=【WCLC 2017】FLAURA研究伴随诊断结果公布：血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7181116656ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534343, encodeId=271615343431e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=第三代抗肿瘤EGFR抑制剂获批进入临床研究, objectType=article, longId=116328, objectId=1d56116328ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d56116328ae, replyNumber=0, likeNumber=69, createdTime=2017-10-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d56116328ae, moduleTitle=第三代抗肿瘤EGFR抑制剂获批进入临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d56116328ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534342, encodeId=cf381534342f0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=【WCLC 2017】陆舜教授：呋喹替尼联合吉非替尼治疗EGFR突变晚期NSCLC安全性良好，双口服靶向药物潜力值得进一步研究, objectType=article, longId=116321, objectId=ad9011632187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad9011632187, replyNumber=0, likeNumber=59, createdTime=2017-10-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad9011632187, moduleTitle=【WCLC 2017】陆舜教授：呋喹替尼联合吉非替尼治疗EGFR突变晚期NSCLC安全性良好，双口服靶向药物潜力值得进一步研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad9011632187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534341, encodeId=56b0153434179, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：IMPRESS研究公布最终OS结果：耐药后EGFR –TKI原药能不能继续使用？, objectType=article, longId=116014, objectId=6fb0116014fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fb0116014fb, replyNumber=0, likeNumber=57, createdTime=2017-10-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fb0116014fb, moduleTitle=JCO：IMPRESS研究公布最终OS结果：耐药后EGFR –TKI原药能不能继续使用？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fb0116014fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：ASP8273治疗EGFR突变非小细胞肺癌

2017-12-19

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Sci Rep：计算机辅助结节评估和风险收益（CANARY）可以促进对肺腺癌EGFR突变状态的非侵入性预测

2017-12-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CFDA批准上市Giotrif®（阿法替尼），单药治疗EGFR敏感突变的晚期非小细胞肺癌

2017-12-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：BGJ398治疗FGFR改变晚期胆管癌

2017-12-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药

2017-11-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet oncol：吉非替尼相比长春瑞滨联合顺铂治疗，可显著延长携带EGFR突变的晚期非小细胞肺癌术后患者的无病存活期。

2017-11-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：EGFR扩增胶质瘤中EGFRvⅢ阳性的预后意义

2017-11-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

阿法替尼（吉泰瑞®）--第二代EGFR-TKI肺癌靶向药物在中国获批

2017-11-19

liuyiping (审核中...)

前往app查看评论内容

#GFR#

陈建华教授：晚期NSCLC一线EGFR-TKI耐药进展后的治疗策略

2017-11-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

刘晓晴教授对话张树才教授：三代EGFR-TKI的对比与排兵布阵

2017-11-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Exp Clin Cancer Res：circGFRA1或是三阴乳腺癌潜在的治疗靶点

2017-11-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点

2017-11-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol：血液肿瘤DNA测序指导EGFR阳性肺癌两种靶向药物序贯使用

2017-10-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Brit J Cancer：RAS野生型转移性结肠癌患者接受抗EGFR治疗响应的蛋白预测生物标志物

2017-10-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

【WCLC 2017】韩宝惠教授解读安罗替尼更新数据：EGFR野生和突变型安罗替尼均获得双阳性结果

2017-10-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

[WCLC精彩研究]支气管镜冲洗液用于EGFR突变检测

2017-10-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

【WCLC 2017】FLAURA研究伴随诊断结果公布：血浆EGFR突变阳性与组织阳性患者接受奥希替尼一线治疗获益一致

2017-10-20

liuyiping (审核中...)

前往app查看评论内容

#GFR#

第三代抗肿瘤EGFR抑制剂获批进入临床研究

2017-10-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

【WCLC 2017】陆舜教授：呋喹替尼联合吉非替尼治疗EGFR突变晚期NSCLC安全性良好，双口服靶向药物潜力值得进一步研究

2017-10-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：IMPRESS研究公布最终OS结果：耐药后EGFR –TKI原药能不能继续使用？

2017-10-14

科室
- - 订阅+
  - 更多科室
工具
服务